Tuesday, March 31, 2015

BioCryst Recieves $12M to Develop Ebola Drug

Durham-based BioCryst Pharmaceuticals is receiving $12 million from the federal government to fund further development of a possible drug to treat the deadly Ebola virus.

No comments:

Post a Comment